(TABLE 1) When the addition of bevacizumab, a monoclonal antibody (mAb) inhibiting VEGF, to chemotherapy for advanced colorectal cancer (CRC) offered an almost 5 month survival benefit, considerable effort was directed to develop other angiogenesis blockers[14]. Here, VEGFA is linked to colorectal cancer.